Alliance Pharma (LSE:APH) EPS (Basic) : £-0.01 (TTM As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma EPS (Basic)?

Alliance Pharma's basic earnings per share (Basic EPS) for the six months ended in Jun. 2023 was £0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.01.

Alliance Pharma's EPS (Diluted) for the six months ended in Jun. 2023 was £0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.01.

Alliance Pharma's EPS without NRI for the six months ended in Jun. 2023 was £0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was 0.03.

During the past 12 months, Alliance Pharma's average EPS without NRIGrowth Rate was -52.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -5.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -0.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Alliance Pharma's highest 3-Year average EPS without NRI Growth Rate was 184.40% per year. The lowest was -75.00% per year. And the median was 4.70% per year.

Alliance Pharma EPS (Basic) Historical Data

The historical data trend for Alliance Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma EPS (Basic) Chart

Alliance Pharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

0.04

0.05

0.02

0.01

Alliance Pharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EPS (Basic)	Get a 7-Day Free Trial															0.02	-	0.02	-0.02	0.01

Alliance Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Alliance Pharma's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0.936	-	0)	/	539.480
	=	0.00

Alliance Pharma's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(5.109	-	0)	/	540.039
	=	0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01

Alliance Pharma (LSE:APH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Alliance Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).